A pilot study of the telomerase inhibitor imetelstat for myelofibrosis

New England Journal of Medicine

Volumn 373, Issue 10, 2015, Pages 908-919

  Tefferi, Ayalew ^a   Lasho, Terra L ^a   Begna, Kebede H ^a   Patnaik, Mrinal M ^a   Zblewski, Darci L ^a   Finke, Christy M ^a   Laborde, Rebecca R ^a   Wassie, Emnet ^a   Schimek, Lauren ^a   Hanson, Curtis A ^b   Gangat, Naseema ^a   Wang, Xiaolin ^c   Pardanani, Animesh ^a  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

^c GERON CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; IMETELSTAT; JANUS KINASE 2; AMINOTRANSFERASE; INDOLE DERIVATIVE; JAK2 PROTEIN, HUMAN; NICOTINAMIDE; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASXL1 GENE; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; FEVER; GENE; GENE MUTATION; HEMATOMA; HOT FLUSH; HUMAN; HUMAN CELL; INFUSION RELATED REACTION; INJECTION SITE PAIN; JAK2 GENE; LUNG INFECTION; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; NAUSEA; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; REMISSION; SF3B1 GENE; SKIN BRUISING; SKIN INFECTION; TELOMERE HOMEOSTASIS; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT RESPONSE; U2AF1 GENE; UPPER GASTROINTESTINAL BLEEDING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; FIBROSIS; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA;

AGED; BONE MARROW CELLS; DNA MUTATIONAL ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROSIS; HUMANS; INDOLES; INFUSIONS, INTRAVENOUS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; NIACINAMIDE; PILOT PROJECTS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; REMISSION INDUCTION; TELOMERASE; THROMBOCYTHEMIA, ESSENTIAL; TRANSAMINASES;

EID: 84940845882     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1310523     Document Type: Article

References (34)

1. Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol 2015; 1: 97-105.
2. Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012; 119: 2721-30.
3. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789-96
4. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787-98.
5. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
6. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013; 27: 1322-7.
7. Moyzis RK, Buckingham JM, Cram LS, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 1988; 85: 6622-6.
8. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 2006; 12: 1133-8.
9. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345: 458-60.
10. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990; 346: 866-8.
11. Greider CW, Blackburn EH. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 1987; 51: 887-98.
12. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989; 59: 521-9.
13. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985; 43: 405-13.
14. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-5.
15. Park JI, Venteicher AS, Hong JY, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009; 460: 66-72.
16. Ghosh A, Saginc G, Leow SC, et al. Telomerase directly regulates NF-κBdependent transcription. Nat Cell Biol 2012; 14: 1270-81.
17. Maida Y, Yasukawa M, Furuuchi M, et al. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 2009; 461: 230-5.
18. Ouellette MM, Wright WE, Shay JW. Targeting telomerase-expressing cancer cells. J Cell Mol Med 2011; 15: 1433-42.
19. Röth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L) - telomerasebased cancer therapy. Recent Results Cancer Res 2010; 184: 221-34.
20. Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med 2015; 373: 920-8.
21. Ruella M, Salmoiraghi S, Risso A, et al. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. Exp Hematol 2013; 41: 627-34.
22. Spanoudakis E, Bazdiara I, Pantelidou D, et al. Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms. Leuk Res 2011; 35: 459-64.
23. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-51.
24. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of postpolycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437-8.
25. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-7.
26. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013; 122: 1395-8.
27. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128-32.
28. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861-9.
29. Tefferi A, Finke CM, Lasho TL, et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia 2014; 28: 431-3.
30. Broséus J, Alpermann T, Wulfert M, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013; 27: 1826-31.
31. Box JA, Bunch JT, Tang W, Baumann P. Spliceosomal cleavage generates the 3′ end of telomerase RNA. Nature 2008; 456: 910-4.
32. Tang W, Kannan R, Blanchette M, Baumann P. Telomerase RNA biogenesis involves sequential binding by Sm and Lsm complexes. Nature 2012; 484: 260-4.
33. Kannan R, Hartnett S, Voelker RB, Berglund JA, Staley JP, Baumann P. Intronic sequence elements impede exon ligation and trigger a discard pathway that yields functional telomerase RNA in fission yeast. Genes Dev 2013; 27: 627-38.
34. de Lange T, Jacks T. For better or worse? Telomerase inhibition and cancer. Cell 1999; 98: 273-5.